Here are five points:
1. The new course will focus on applying financing methods in the healthcare industry to create an environment for drug discovery, clinical development and better patient access to costly therapies.
2. The course will leverage financial techniques like portfolio theory, securitization and derivative securities to fit biomedical contexts.
3. Specific course topics include:
- Financial analysis for life sciences professionals
- Historical financial risks and returns of biotech and pharmaceutical industries
- Mechanics of biotech startup financing
- Capital budgeting for pharmaceutical companies
- Applications of financial engineering in drug royalty investment companies, biomedical megafunds, drug approval swaps and life sciences investment banking
4. The Charles E. and Susan T. Harris Professor, Andrew W. Lo, PhD, will teach the healthcare finance course.
5. Dr. Lo also serves as the director of the Laboratory for Financial Engineering at MIT Sloan.
More articles on practice management:
10 things to know on the Medicare Shared Savings Program & Pioneer ACO — Savings reach $1.29B in 3 years
Do you want to be a Mazda or a Maserati? Dr. Robert Gray on the evolution of hand surgery & how value-based care will impact clinical outcomes
Experiences in Emergency Medince: Q&A with Dr. Michael Boyle of ECI Healthcare Partners
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
